Exemplary results in the 2012 Phase III trial coined EMILIA has led Roche Pharmaceuticals to initiate additional Phase III trials evaluating trastuzumab emtansine. The New Year brings registration trials for newly diagnosed as well as previously treated metastatic HER2-positive breast cancer patients. Trastuzumab will be evaluated in this 2013 study for three settings in earlier-stage[…]
New Phase III Trials to Begin for Trastuzumab in 2013
Chemotherapeutic / Anti-Neoplastic, Drug Research & Development API, Monoclonal Antibodies / mAb Tags: 180288-69-1AnthracyclineschemotherapyHER2-positiveHerceptinTrastuzumab Jan 14, 2013
New Drugs and Therapies at the Forefront of treatment for Acute Lymphoblastic Leukemia
Bulk Active Ingredient, Chemotherapeutic / Anti-Neoplastic, FDA Approval News, Immunosuppressant Tags: acute lymphoblastic leukemiaHerceptinimatinibleukemiaMethotrexateTrastuzumab Mar 30, 2012
J.R.Stokes Illustrations: Natural Killer: T-cell vs. Leukemia Researchers received encouraging news on March 22, 2012, with the information that the novel drug to treat acute lymphoblastic leukemia, known as Marqibo won an FDA panel vote. The group of oncology advisers voted 7-4 endorsing the Vincristine Sulfate CAS# 2068-78-2 liposomal injection, also known as the brand[…]
Trastuzumab and Chemo Combo for Advanced Gastroesophageal Junction Cancer
Monoclonal Antibodies / mAb Tags: 180288-69-1chemotherapyHER2-positiveHerceptinTrastuzumab May 16, 2011
A study conducted by the Seoul National University College of Medicine, Seoul in South Korea found that the monoclonal antibody, Trastuzumab (Herceptin) used with chemotherapeutic drugs in the treatment of HER2-positive advanced gastroesophageal junction cancer showed a promising new treatment option for patients. HER2 protein is responsible for cell growth and division and the cell[…]
Monoclonal Antibodies (mAbs) – Growth, Supply, and Uses for Cancer Treatment
Antithrombotic, Chemotherapeutic / Anti-Neoplastic, Drug Research & Development API, Monoclonal Antibodies / mAb Tags: 180288-69-1331731-18-1AdalimumabAlemtuzumabBevacizumabchemotherapyEGFRRituximabTrastuzumab Feb 11, 2011
What Are Monoclonal Antibodies? A monoclonal antibody is a laboratory-produced molecule that’s carefully engineered to attach to specific defects in your cancer cells. Monoclonal antibodies mimic the antibodies your body naturally produces as part of your immune system’s response to germs, vaccines and other invaders. Growing Interest for Monoclonal Antibody Therapies Monoclonal antibodies were initially[…]
